Trial Profile
Phase I trial of alofanib (RPT835) in combination with paclitaxel and carboplatin for the treatment of platinum-resistant ovarian cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Alofanib (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2015 New trial record